IRIS
SGHERZA, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 658
AS - Asia 550
EU - Europa 447
SA - Sud America 141
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.819
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 642
SG - Singapore 265
IT - Italia 169
BR - Brasile 115
HK - Hong Kong 94
CN - Cina 90
RU - Federazione Russa 84
SE - Svezia 49
VN - Vietnam 48
DE - Germania 35
GB - Regno Unito 24
FR - Francia 22
CI - Costa d'Avorio 14
ID - Indonesia 12
AR - Argentina 11
FI - Finlandia 10
AT - Austria 9
BE - Belgio 9
CA - Canada 8
JP - Giappone 8
NL - Olanda 8
BD - Bangladesh 7
IN - India 7
PL - Polonia 7
IE - Irlanda 6
EC - Ecuador 5
MX - Messico 5
TR - Turchia 5
CL - Cile 3
CZ - Repubblica Ceca 3
PY - Paraguay 3
TW - Taiwan 3
ZA - Sudafrica 3
AZ - Azerbaigian 2
CH - Svizzera 2
CO - Colombia 2
ES - Italia 2
EU - Europa 2
KR - Corea 2
TH - Thailandia 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BO - Bolivia 1
BY - Bielorussia 1
CU - Cuba 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
IQ - Iraq 1
JM - Giamaica 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
Totale 1.819
Salva come PNG Salva come JPEG
Città #
Singapore 145
Ashburn 120
Hong Kong 74
Fairfield 46
Beijing 44
Chandler 43
Nyköping 42
Los Angeles 29
Woodbridge 29
Seattle 28
Houston 23
New York 23
Bari 22
Milan 19
Wilmington 18
Ho Chi Minh City 17
Abidjan 14
Ann Arbor 14
Cambridge 14
Jakarta 11
Lawrence 11
Inglewood 10
Brussels 9
Des Moines 9
Frankfurt am Main 9
London 9
Hanoi 8
Helsinki 8
Roxbury 8
Gesualdo 7
Munich 7
Nuremberg 7
Santa Clara 7
Buffalo 6
Falkenstein 6
Moscow 6
Vienna 6
Brooklyn 5
Chicago 5
San Diego 5
São Paulo 5
Warsaw 5
Alcamo 4
Atlanta 4
Bitonto 4
Dallas 4
Dublin 4
Florianópolis 4
Imbersago 4
Istanbul 4
Modugno 4
Naples 4
Princeton 4
Tokyo 4
Avellino 3
Belo Horizonte 3
Chennai 3
Chiswick 3
Denver 3
Florence 3
Guangzhou 3
Hải Dương 3
Johannesburg 3
Palermo 3
Paris 3
Phú Thọ 3
San Francisco 3
Taranto 3
Verona 3
Andria 2
Aparecida de Goiânia 2
Baku 2
Bauru 2
Bengaluru 2
Betim 2
Bisceglie 2
Boston 2
Brasília 2
Brno 2
Bà Rịa 2
Bắc Ninh 2
Campinas 2
Cariacica 2
Chiang Mai 2
Curitiba 2
Dearborn 2
Edinburgh 2
Fragagnano 2
Guayaquil 2
Hefei 2
Itri 2
Jacksonville 2
Joinville 2
Magé 2
Nagano 2
Nanjing 2
Norwalk 2
Nova Iguaçu 2
Parabita 2
Parma 2
Totale 1.088
Salva come PNG Salva come JPEG
Nome #
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 149
Challenges and opportunities of MicroRNAs in lymphomas 121
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 107
null 96
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 92
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 89
What Is New in the Treatment of Smoldering Multiple Myeloma? 85
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 84
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 75
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 69
null 68
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 65
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 57
Dasatinib first-line: Multicentric Italian experience outside clinical trials 53
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 50
Implications of interleukin-6 (Il-6)-blockade for severe covid-19 infection in patients with multiple myeloma 47
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases 46
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 45
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy 44
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 44
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 42
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials 39
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese” 37
Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments 35
Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: “Chance or Causality?” 35
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 33
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 33
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by AB0 blood group in subjects with transfusion-dependent thalassemia 32
Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review 30
Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study 29
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease 29
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 22
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry 22
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese 7
Totale 1.911
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.607
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202140 0 0 0 0 0 13 3 6 6 4 7 1
2021/2022120 21 8 0 8 6 9 14 5 5 7 21 16
2022/2023139 14 29 14 7 5 16 4 24 20 0 6 0
2023/2024186 26 31 26 8 15 28 28 5 0 0 6 13
2024/2025591 22 7 30 24 16 71 69 57 21 17 104 153
2025/2026662 183 58 90 132 175 24 0 0 0 0 0 0
Totale 1.911